Gemcitabine and carboplatin combination chemotherapy for elderly patients with advanced Non-Small Cell Lung Cancer: a feasibility study.
OBJECTIVE
Although platinum based chemotherapy is known to improve the survival duration for the patients with non-small cell lung cancer, the role of platinum for elderly patient is not yet clear. We administered gemcitabine and carboplatin combination therapy to elderly patients with NSCLC. The aim of this study was to evaluate the efficacy and toxicities of this regimen for elderly patients.


METHODS
THE ELIGIBILITY CRITERIA WERE AS FOLLOWS: pathologically confirmed NSCLC, an age >or=65 years, advanced disease with stage IIIB or IV and the patients were chemotherapy-naive. The treatment regimen was as follows; gemcitabine 1,000 mg/m(2) was administered on days 1 and 8 and carboplatin AUC=5 was administered on day 1. This regimen was repeated every 3 weeks. The efficacy was evaluated in terms of the response rate, the time to progression and the overall survival duration.


RESULTS
From Dec 2001 to Feb 2005, a total of 20 patients were entered into this study. The median patient age was 68 years (range: 65 approximately 75). 19 patients were evaluable for their treatment response. A partial response was obtained in 8 patients (response rate: 42.1%, 95% CI: 19.4 approximately 64.8%). The median time to progression and the survival duration were 136 days and 453 days, respectively. Among a total of 65 cycles of treatment, grade 3 or 4 leukopenia and thrombocytopenia were observed in 7.7% and 13.9% of the cycles, respectively. Grade 3 or 4 vomiting was observed in 7.7% of the cycles. Grade 3 skin rash developed in 1.5% of the cycles. 1 patient died of septic shock after chemotherapy.


CONCLUSIONS
Gemcitabine and carboplatin combination chemotherapy was relatively safe and effective for treating elderly patients with NSCLC.
Yuh
Young Jin
YJ
Department of Internal Medicine, College of Medicine, Inje University, Sanggye Paik Hospital, Seoul, Korea. yjyuh@paik.ac.kr
Lee
Hyo Rak
HR
Kim
Sung Rok
SR
J Thorac Oncol. 2006 Jan;1(1):19-24
17409822
N Engl J Med. 1999 Dec 30;341(27):2061-7
10615079
Ann Oncol. 2000 Oct;11(10):1295-300
11106119
J Clin Oncol. 1990 Sep;8(9):1556-62
2167953
N Engl J Med. 2002 Jan 10;346(2):92-8
11784875
J Clin Oncol. 2005 Nov 20;23(33):8380-8
16293868
Lancet Oncol. 2001 Sep;2(9):533-43
11905707
J Clin Oncol. 2001 Feb 15;19(4):1064-70
11181670
Lung Cancer. 2003 Jul;41(1):81-9
12826316
BMJ. 1995 Oct 7;311(7010):899-909
7580546
J Clin Oncol. 1999 Mar;17(3):921-6
10071285
Cancer. 2000 Jul 15;89(2):328-33
10918162
J Clin Oncol. 1999 Jan;17(1):12-8
10458212
J Clin Oncol. 1999 Jan;17(1):409-22
10458260
Eur J Cancer. 1997 Dec;33(14):2313-4
9616273
J Clin Oncol. 2005 May 1;23(13):3125-37
15860872
J Natl Cancer Inst. 1999 Jan 6;91(1):66-72
9890172
Anticancer Res. 2002 Sep-Oct;22(5):3053-6
12530041
Lung Cancer. 2000 Feb;27(2):75-80
10688490